| Heart failure
Atorvaliq vs Samsca
Side-by-side clinical, coverage, and cost comparison for heart failure.Deep comparison between: Atorvaliq vs Samsca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSamsca has a higher rate of injection site reactions vs Atorvaliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Samsca but not Atorvaliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Atorvaliq
Samsca
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor
Oral
Daily
Vasopressin V2-receptor antagonist
Indications
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Hyperlipidemia
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Hyponatremia
- Heart failure
- Inappropriate ADH Syndrome
Dosing
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Hyponatremia, Heart failure, Inappropriate ADH Syndrome Start at 15 mg once daily; titrate at intervals >=24 hours to 30 mg once daily, then to a maximum of 60 mg once daily as needed; initiate and re-initiate in a hospital; do not administer for more than 30 days.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
- Autosomal dominant polycystic kidney disease (ADPKD) outside of FDA-approved REMS
- Unable to sense or respond to thirst
- Hypovolemic hyponatremia
- Concomitant use of strong CYP3A inhibitors
- Anuria
- Hypersensitivity to tolvaptan or any components of the product
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=5%) Thirst, dry mouth, asthenia, constipation, pollakiuria or polyuria, hyperglycemia
Serious Disseminated intravascular coagulation, intracardiac thrombus, ventricular fibrillation, ischemic colitis, diabetic ketoacidosis, rhabdomyolysis, cerebrovascular accident, pulmonary embolism, respiratory failure, deep vein thrombosis
Postmarketing Osmotic demyelination syndrome, hypernatremia, hypersensitivity reactions including anaphylactic shock and generalized rash
Pharmacology
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
Tolvaptan is a selective vasopressin V2-receptor antagonist that blocks vasopressin's renal effect, promoting free water excretion (aquaresis) and raising serum sodium concentrations without significantly affecting urinary sodium or potassium excretion.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Atorvaliq.
Samsca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
No coverage data available for Atorvaliq.
Samsca
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Humana
No coverage data available for Atorvaliq.
Samsca
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Atorvaliq.
$0
Otsuka Patient Assistance Foundation (OPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AtorvaliqView full Atorvaliq profile
SamscaView full Samsca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.